Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
21-40 of 847 trials

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

Eosinophilic Gastritis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Severe Eosinophilic Asthma: Benralizumab for Kids

We are studying whether benralizumab can help children with severe eosinophilic asthma by reducing asthma attacks and improving their symptoms. This trial will also look at the safety of the medication.

Severe Eosinophilic Asthma>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Atopic Dermatitis: Lebrikizumab for Kids

We are studying a new treatment for children and teens with moderate-to-severe atopic dermatitis. The goal is to see if it works better than a placebo when used alongside standard treatments.

Atopic Dermatitis (Eczema)3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesDermatology

Multiple Myeloma: Iberdomide vs. Lenalidomide Maintenance Therapy

We are comparing two treatments for newly diagnosed multiple myeloma patients after stem cell transplant to see which one may help keep the disease from worsening. This study will also look at safety and quality of life for participants.

Newly Diagnosed Multiple Myeloma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Osimertinib (TAGRISSO) Continuation Study

We are providing ongoing treatment with osimertinib for patients who have benefited from it in a previous study. The goal is to monitor safety and tolerability as they continue their treatment.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Triple-Negative Breast Cancer: Tiragolumab and Atezolizumab with Chemotherapy

We are studying a combination of two immunotherapy drugs with chemotherapy for patients with triple-negative breast cancer. This trial aims to evaluate the treatment's effectiveness and safety in both early and advanced stages of the disease.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Stroke Prevention in Kidney Disease: Apixaban Study

We are studying whether apixaban can safely reduce the risk of strokes in patients with chronic kidney disease stage 5 and atrial fibrillation. This trial will help us understand its effects compared to standard care.

Atrial Fibrillation with Chronic Kidney Disease Stage 5>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Ovarian Cancer: Mirvetuximab Soravtansine with Bevacizumab

We are studying a new treatment combining mirvetuximab soravtansine and bevacizumab for adults with recurrent ovarian cancer who have not progressed after chemotherapy. The goal is to see if this combination helps patients live longer without their cancer worsening.

Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology